What genetic mutations are commonly found in Non-Small Cell Lung Cancer

Common Genetic Mutations in Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC) frequently develops from specific genetic mutations—abnormal changes in genes that cause cancer cells to grow uncontrollably. Understanding these mutations is important because they directly influence which treatments may work best for your situation.

The Most Common Driver Mutations

According to the NCCN Guidelines for NSCLC, doctors look for several key mutations that are "actionable"—meaning targeted treatments exist specifically for them:

EGFR Mutations (Most Common)

EGFR (Epidermal Growth Factor Receptor) mutations are among the most frequently found in NSCLC, particularly in:

• Patients who have never smoked
• Women
• People of Asian descent

What it means: EGFR is a protein on the surface of lung cells that normally controls cell growth. When mutated, it sends constant "grow" signals to cancer cells. The most common EGFR mutations are:

• Exon 19 deletions and L858R point mutations — these typically respond very well to targeted drugs called EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib
• Exon 20 insertions — these require different treatment approaches than the common mutations

According to NCCN Guidelines, EGFR testing should be performed when TKI therapy is being considered for stage IB–IIIC NSCLC and beyond.

ALK Rearrangements

ALK (Anaplastic Lymphoma Kinase) rearrangements occur in about 3-5% of NSCLC cases, most commonly in:

• Younger patients
• Never-smokers
• Adenocarcinoma histology

What it means: The ALK gene becomes fused with another gene, creating an abnormal protein that drives cancer growth. This mutation responds well to targeted ALK inhibitors like alectinib, brigatinib, and lorlatinib. The NCCN Guidelines recommend ALK testing as a Category 1 priority (highest recommendation level) for patients with metastatic nonsquamous NSCLC.

KRAS Mutations

KRAS mutations are the most common mutation in North American adenocarcinomas, found in approximately 25% of cases.

What it means: KRAS is a protein involved in cell growth signaling. When mutated, it continuously activates growth pathways. KRAS mutations are associated with:

• Cigarette smoking history
• Shorter survival compared to wild-type (unmutated) KRAS
• Generally lower response rates to immunotherapy alone (~26% for single-agent immune checkpoint inhibitors)

Important note: Patients with specific KRAS mutations (particularly G12C mutations) now have targeted therapy options like sotorasib and adagrasib available.

HER2 (ERBB2) Mutations

HER2 mutations occur in approximately 3% of advanced nonsquamous NSCLC cases.

What it means: HER2 is another growth-promoting protein. When mutated, it can be targeted with specific therapies. According to NCCN Guidelines, HER2 testing is now recommended for all patients with metastatic nonsquamous NSCLC or NSCLC NOS. Patients with HER2 mutations tend to be:

• Women who have never smoked
• At higher risk for brain metastases

MET Alterations (METex14 Skipping Mutations)

MET mutations occur in 3-4% of adenocarcinoma NSCLC cases.

What it means: MET is a growth factor receptor. When exon 14 is "skipped," the protein becomes overactive. These mutations are more common in older women who have never smoked and respond to targeted MET inhibitors.

Other Important Mutations

The NCCN Guidelines also recommend testing for:

• BRAF mutations (particularly p.V600E)
• ROS1 rearrangements
• RET rearrangements
• NTRK1/2/3 gene fusions

Each of these has specific targeted therapies available.

Why Testing Matters

According to NCCN Guidelines, the Panel "strongly advises broader molecular profiling to identify these and other rare driver mutations for which targeted therapies may be available to ensure that patients receive the most appropriate treatment."

Key principle: If you have a driver mutation, targeted therapy (which attacks the specific mutation) is typically more effective and causes fewer side effects than standard chemotherapy, which damages all fast-growing cells indiscriminately.

Testing Methods

The NCCN Guidelines note that Next-Generation Sequencing (NGS) is preferred for comprehensive mutation detection because it can identify a broad range of alterations in a single test. Real-time PCR and other methods may miss certain mutations, particularly EGFR exon 20 insertions.

Questions to Ask Your Healthcare Team

1. Has my tumor been tested for driver mutations? If not, why not?
2. Which specific mutations was my tumor tested for? (Ask for the complete list)
3. What were the results of my molecular testing? (Request a copy of the report)
4. If a driver mutation was found, what treatment options does it open up for me?
5. If no driver mutation was found, what does that mean for my treatment approach?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.